$SKYE
Skye Bioscience, Inc.

2022 Q1 Form 10-Q Financial Statement

#000151655122000006 Filed on May 06, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.622M $1.128M
YoY Change 43.88% -20.12%
% of Gross Profit
Research & Development $1.266M $609.7K
YoY Change 107.6% -23.76%
% of Gross Profit
Depreciation & Amortization $26.98K $938.00
YoY Change 2776.12% 156.99%
% of Gross Profit
Operating Expenses $2.888M $1.737M
YoY Change 66.24% -21.43%
Operating Profit -$2.888M -$1.737M
YoY Change 66.24% -21.43%
Interest Expense $199.0K $184.9K
YoY Change 7.64% 11.15%
% of Operating Profit
Other Income/Expense, Net -$155.4K -$423.3K
YoY Change -63.29% 224.45%
Pretax Income -$3.043M -$2.161M
YoY Change 40.86% -7.74%
Income Tax
% Of Pretax Income
Net Earnings -$3.043M -$2.161M
YoY Change 40.86% -7.74%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01 -$0.01
Diluted Earnings Per Share -$0.01 -$0.01
COMMON SHARES
Basic Shares Outstanding 495.8M shares 336.9M shares
Diluted Shares Outstanding 495.8M shares 336.9M shares

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.007M $5.152M
YoY Change 16.58% 813.78%
Cash & Equivalents $6.007M $5.152M
Short-Term Investments
Other Short-Term Assets $109.8K $229.2K
YoY Change -52.11% 113.19%
Inventory
Prepaid Expenses $822.5K
Receivables
Other Receivables
Total Short-Term Assets $6.993M $5.382M
YoY Change 29.94% 701.6%
LONG-TERM ASSETS
Property, Plant & Equipment $80.77K $17.10K
YoY Change 372.36% 955.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $8.309K
YoY Change
Total Long-Term Assets $218.0K $17.10K
YoY Change 1175.0% 955.49%
TOTAL ASSETS
Total Short-Term Assets $6.993M $5.382M
Total Long-Term Assets $218.0K $17.10K
Total Assets $7.211M $5.399M
YoY Change 33.56% 702.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $878.7K $499.9K
YoY Change 75.8% -48.9%
Accrued Expenses $540.7K $175.1K
YoY Change 208.75% 391.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.130M $103.5K
YoY Change 1957.32%
Total Short-Term Liabilities $4.182M $1.384M
YoY Change 202.08% -16.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $1.536M
YoY Change -100.0% 196.61%
Other Long-Term Liabilities $55.91K
YoY Change
Total Long-Term Liabilities $55.91K $1.536M
YoY Change -96.36% 116.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.182M $1.384M
Total Long-Term Liabilities $55.91K $1.536M
Total Liabilities $4.238M $2.920M
YoY Change 45.12% 22.9%
SHAREHOLDERS EQUITY
Retained Earnings -$50.30M -$40.89M
YoY Change 23.0%
Common Stock $53.27M $43.37M
YoY Change 22.82%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.973M $2.479M
YoY Change
Total Liabilities & Shareholders Equity $7.211M $5.399M
YoY Change 33.56% 702.21%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$3.043M -$2.161M
YoY Change 40.86% -7.74%
Depreciation, Depletion And Amortization $26.98K $938.00
YoY Change 2776.12% 156.99%
Cash From Operating Activities -$2.915M -$1.348M
YoY Change 116.22% 6.47%
INVESTING ACTIVITIES
Capital Expenditures $1.999K $10.70K
YoY Change -81.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.999K -$10.70K
YoY Change -81.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -$59.26K $4.042M
YoY Change -101.47%
NET CHANGE
Cash From Operating Activities -$2.915M -$1.348M
Cash From Investing Activities -$1.999K -$10.70K
Cash From Financing Activities -$59.26K $4.042M
Net Change In Cash -$2.976M $2.683M
YoY Change -210.93% -311.91%
FREE CASH FLOW
Cash From Operating Activities -$2.915M -$1.348M
Capital Expenditures $1.999K $10.70K
Free Cash Flow -$2.917M -$1.359M
YoY Change 114.67% 7.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001516551
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
000-55136
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
Skye Bioscience, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-0692882
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
11250 El Camino Real,
CY2022Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2022Q1 dei City Area Code
CityAreaCode
858
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
410-0266
CY2022Q1 dei Security12g Title
Security12gTitle
Common Stock, par value $0.001
CY2022Q1 dei Trading Symbol
TradingSymbol
SKYE
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
495925112 shares
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6006869 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8983007 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4572 USD
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4571 USD
CY2022Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
822541 USD
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
554217 USD
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q1 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
48908 USD
CY2021Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
13432 USD
CY2022Q1 us-gaap Other Assets Current
OtherAssetsCurrent
109750 USD
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
56870 USD
CY2022Q1 us-gaap Assets Current
AssetsCurrent
6992640 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
9612097 USD
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
80768 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
87710 USD
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
128935 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
146972 USD
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8309 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8309 USD
CY2022Q1 us-gaap Assets
Assets
7210652 USD
CY2021Q4 us-gaap Assets
Assets
9855088 USD
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
878720 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
897880 USD
CY2022Q1 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
24026 USD
CY2021Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
2130 USD
CY2022Q1 skye Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
218039 USD
CY2021Q4 skye Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
174911 USD
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
237037 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
344450 USD
CY2022Q1 us-gaap Loans Payable Current
LoansPayableCurrent
214307 USD
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
0 USD
CY2022Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
378106 USD
CY2021Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
375842 USD
CY2022Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
16077 USD
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
59732 USD
CY2022Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
450000 USD
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
450000 USD
CY2022Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1679741 USD
CY2021Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1524905 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
85601 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
82372 USD
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4181654 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3912222 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55906 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
78700 USD
CY2022Q1 us-gaap Liabilities
Liabilities
4237560 USD
CY2021Q4 us-gaap Liabilities
Liabilities
3990922 USD
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
495925112 shares
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
495925112 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
476108445 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
476108445 shares
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
495925 USD
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
476108 USD
CY2022Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52776729 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
52644221 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50299562 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47256163 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2973092 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5864166 USD
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7210652 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9855088 USD
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1265653 USD
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
609656 USD
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1622368 USD
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1127606 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2888021 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
1737262 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2888021 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1737262 USD
CY2022Q1 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
-43655 USD
CY2021Q1 skye Change In Fair Value Of Derivative Liabilities
ChangeInFairValueOfDerivativeLiabilities
238350 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
199033 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
184905 USD
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-155378 USD
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-423255 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3043399 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2160517 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3043399 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
495823445 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
336883489 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
495823445 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
336883489 shares
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3043399 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2022Q1 us-gaap Depreciation
Depreciation
26978 USD
CY2021Q1 us-gaap Depreciation
Depreciation
938 USD
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
137358 USD
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
146580 USD
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
43655 USD
CY2021Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-238350 USD
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
154836 USD
CY2021Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
141490 USD
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7213 USD
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
34199 USD
CY2022Q1 skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
35476 USD
CY2021Q1 skye Increase Decrease In Prepaid Expenses Due From Related Parties
IncreaseDecreaseInPrepaidExpensesDueFromRelatedParties
0 USD
CY2022Q1 skye Increase Decrease In Other Assets Due From Related Parties
IncreaseDecreaseInOtherAssetsDueFromRelatedParties
52880 USD
CY2021Q1 skye Increase Decrease In Other Assets Due From Related Parties
IncreaseDecreaseInOtherAssetsDueFromRelatedParties
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-19160 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
135514 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
21896 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-7032 USD
CY2022Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
43128 USD
CY2021Q1 us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-958 USD
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-107413 USD
CY2021Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
70448 USD
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-19565 USD
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0 USD
CY2022Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
15264 USD
CY2021Q1 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
121298 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2914875 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1348088 USD
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1999 USD
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10696 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1999 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5156992 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10696 USD
CY2022Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
61230 USD
CY2021Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-59263 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4041800 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2976137 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2683016 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8987578 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2473976 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6011441 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5156992 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6006869 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5152425 USD
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4572 USD
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
4567 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6011441 USD
CY2021Q1 skye Financing Of Insurance Premium
FinancingOfInsurancePremium
0 USD
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
44087 USD
CY2022Q1 skye Financing Of Insurance Premium
FinancingOfInsurancePremium
275537 USD
CY2022Q1 skye Accrued Financing Charges
AccruedFinancingCharges
13000 USD
CY2021Q1 skye Accrued Financing Charges
AccruedFinancingCharges
0 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
5864166 USD
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
150358 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3043399 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
2973092 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
450786 USD
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146580 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
2478649 USD
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50299562 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6006869 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2888021 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1737262 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3043399 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2160517 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company’s financial statements include estimates and judgements as to the appropriate carrying values of equity instruments, derivative liabilities, debt with embedded features, and the valuation of stock based compensation awards, which are not readily apparent from other sources.</span></div>
CY2022Q1 skye Research And Development Licensed Technology Costs Capitalized To Date
ResearchAndDevelopmentLicensedTechnologyCostsCapitalizedToDate
0 USD
CY2021Q4 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
2484768 USD
CY2022Q1 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
2559549 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3043399 USD
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3043399 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2160517 USD
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2160517 USD
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
495823445 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
495823445 shares
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
336883489 shares
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
336883489 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q1 skye Class Of Warrant Or Right Warrants Vested And Outstanding
ClassOfWarrantOrRightWarrantsVestedAndOutstanding
134187225 shares
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
59732 USD
CY2022Q1 skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-43655 USD
CY2022Q1 skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 USD
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
16077 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
38567 USD
CY2021Q1 skye Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
0 USD
CY2021Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
238350 USD
CY2021Q1 skye Reclassification Of Derivatives To Equity
ReclassificationOfDerivativesToEquity
0 USD
CY2021Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
276917 USD
CY2021Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
141097 USD
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
430 USD
CY2022Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
43128 USD
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
43129 USD
CY2022Q1 skye Insurance Premium Expense
InsurancePremiumExpense
1069 USD
CY2021Q1 skye Insurance Premium Expense
InsurancePremiumExpense
0 USD
CY2022Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
CY2021Q1 us-gaap Interest Expense Debt
InterestExpenseDebt
286 USD
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
154406 USD
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
393 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
199033 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
184905 USD
CY2022Q1 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
150000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
35405000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.07
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
134750 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
215000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.07
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
825000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.10
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34365000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.07
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
11331250 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.08
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y9M25D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
34365000 shares
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0.07
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M25D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
137358 USD
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146580 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1428815 USD
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 skye Lessee Operating Lease Abatement Term
LesseeOperatingLeaseAbatementTerm
P2M
CY2021Q3 skye Lessee Operating Lease Initial Monthly Rent
LesseeOperatingLeaseInitialMonthlyRent
8067 USD
CY2021Q3 skye Lessee Operating Lease Annual Rent Increase Percent
LesseeOperatingLeaseAnnualRentIncreasePercent
0.03
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
22675 USD
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55906 USD
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M29D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
73089 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
83093 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
156182 USD
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14675 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
141507 USD
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
85601 USD
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
141507 USD

Files In Submission

Name View Source Status
0001516551-22-000006-index-headers.html Edgar Link pending
0001516551-22-000006-index.html Edgar Link pending
0001516551-22-000006.txt Edgar Link pending
0001516551-22-000006-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
skye-20220331.htm Edgar Link pending
skye-20220331.xsd Edgar Link pending
skye-20220331xex311.htm Edgar Link pending
skye-20220331xex312.htm Edgar Link pending
skye-20220331xex321.htm Edgar Link pending
skye-20220331xex322.htm Edgar Link pending
skye-20220331_cal.xml Edgar Link unprocessable
skye-20220331_def.xml Edgar Link unprocessable
skye-20220331_htm.xml Edgar Link completed
skye-20220331_lab.xml Edgar Link unprocessable
skye-20220331_pre.xml Edgar Link unprocessable